Stay updated on Primary Oral Insulin Immunotherapy Clinical Trial

Sign up to get notified when there's something new on the Primary Oral Insulin Immunotherapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Primary Oral Insulin Immunotherapy Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:49:51.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the dosage or concentration of oral insulin being administered in the GPPAD-POInT Study for the prevention of autoimmune diabetes in children with elevated genetic risk for type 1 diabetes.
    Difference
    0.1%
    Check dated 2024-06-06T14:45:48.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying that researchers are looking for infants aged 4 to 7 months with a high genetic risk for developing beta-cell autoantibodies. The new criteria also outline specific genetic markers and conditions for inclusion and exclusion in the study.
    Difference
    15%
    Check dated 2024-05-22T21:32:27.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:36:39.000Z thumbnail image

Stay in the know with updates to Primary Oral Insulin Immunotherapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Primary Oral Insulin Immunotherapy Clinical Trial page.